source
- Roivant's brepocitinib shows strong Phase 3 results, paving way for uveitis indicationRoivant subsidiary Priovant Therapeutics announced positive Phase 3 data for its anti‑inflammatory drug brepocitinib in patients with non‑infectious uveitis, an eye disease that can cause blindness…
- Roche signs $15 billion ADC partnership with China's Hansoh PharmaRoche has re-entered a partnership with China's Hansoh Pharmaceutical, signing a $15 billion biobucks agreement. The deal covers a broad portfolio of antibody-drug conjugate programs, including tw…